Why We Are Buying Tobira Therapeutics After A 'Failed' Phase 2 NASH Trial? Seeking Alpha, 26 Jul 2016 Tobira Therapeutics (NASDAQ: TBRA ) announced the one-year results of a Phase 2 (CENTAUR) clinical trial in patients with non-alc…